Skip to content

MAYAKU PHARMACEUTICAL DEVELOPMENT

Active Private limited companyfounded 2020active for 6 yearsTechnologiepark-Zwijnaarde 82, 9052 GhentKBO/BCE: BE 0755.350.975

Lifetime

5 annual accounts with figures on one time axis
peak of €104,752 in 2025
€104,752▲ 115%
lowest -€25,490 in 2023
€1,553▼ 67.5%
peak of €35,187 in 2021
€1,291▲ €1,553
€169,192▲ 70.2%
Board1 name since 2020
1 director
Documentsfilings and deeds
04-07-202627 days before the deadline
2025micro format
Gross margin from €48,711 to €104,752Result from €4,785 to €1,553Equity from -€262 to €1,291Debts from €99,389 to €169,192Cash from €23,388 to €76,433

Key points

from the 2025 annual accounts

Turnover

≈ €260,000 estimated

The micro format states no turnover.

Debts

€169,192 99% of the balance sheet
Financial debts 51%Suppliers 3%Taxes and wages 14%Other 32%

Of this, €83,644 falls due within a year.

Staff

2 employees on 31-12-2025
102024102025

In 2025, 1 employee joined and nobody left.

Filings

5 annual accounts since 2021
AprilJune31 JulyOctober20222024

The last five annual accounts were filed 12 to 43 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,250 companies had the same profile as MAYAKU PHARMACEUTICAL DEVELOPMENT has now. Each dot stands for 4 companies, two years later.

94.4%
were still trading
2.7%
stopped another way
2.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency under 10%
  • a profit under 5% of the balance sheet

Another 0.3% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,250 companies, not a prediction for MAYAKU PHARMACEUTICAL DEVELOPMENT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 01-10-2020
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0755350975
Registered office moved from Ghent to Zwijnaarde The registered office moved from Hamerstraat 41 9000 Gent to Technologiepark - Zwijnaarde 82 9052 Zwijnaarde · Gazette deed
First establishment At the time the registered office was still in Gent, Hamerstraat 41.
Incorporation Founding capital of €2,000, 100 shares · Founded by · appointed as director · published on 01-10-2020 · Gazette deed
All 11 events

Comparable companies

same main activity, similar in size and age
Company
MAYAKU PHARMACEUTICAL DEVELOPMENT Ghent €170,483 €104,752 0.8% -
Montefalcone Projects Maarkedal €207,746 €77,350 78.7% -
APR Pharma Courcelles €244,955 €70,657 38.2% -
huMAN Gerpinnes €186,227 €78,630 95.7% -
SUPERBIOTICS Eghezée €183,985 €147,182 -5.3% -
Abella Mar Kapellen €150,376 €36,477 55.8% -
MAKE IT WORK CONSULTING Hamois €220,980 €78,327 95.1% -

These companies have the same main activity as MAYAKU PHARMACEUTICAL DEVELOPMENT: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €150,000 and €245,000, founded between 2019 and 2022.

Official details

Source: KBO
Status
Active since 29-09-2020Normal situation
Registered office
32 active companies are registered at this addressOf these, 1 started in the 12 months before 19 November 2026. Source: KBO register, as of 19 November 2026.
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100and 3 others
Establishment unit
2.308.936.8279052 Ghent, registered on 01-10-2020
Financial year end
31 December
Peppol
Reachable since 05-12-2024
Company details

Annual accounts 2025

€170,483▲ 72.0%
Employeeson 31-12-2025
2▲ 100%
Filing
Filed on 04-07-2026, 27 days before the end of the filing period
Financials

Insights on MAYAKU PHARMACEUTICAL DEVELOPMENT

MAYAKU PHARMACEUTICAL DEVELOPMENT files the micro format. That format states no turnover. The gross margin rose from €43,079 in 2021 to €104,752 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MAYAKU PHARMACEUTICAL DEVELOPMENT

What is the company number of MAYAKU PHARMACEUTICAL DEVELOPMENT?
The company number of MAYAKU PHARMACEUTICAL DEVELOPMENT is 0755.350.975. The VAT number is the same number with BE in front: BE 0755.350.975.
Where is MAYAKU PHARMACEUTICAL DEVELOPMENT based?
The registered office is at Technologiepark-Zwijnaarde 82, 9052 Ghent.Company details
What does MAYAKU PHARMACEUTICAL DEVELOPMENT do?
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
What is the legal form of MAYAKU PHARMACEUTICAL DEVELOPMENT?
MAYAKU PHARMACEUTICAL DEVELOPMENT is a private limited company (BV).
When was MAYAKU PHARMACEUTICAL DEVELOPMENT founded?
MAYAKU PHARMACEUTICAL DEVELOPMENT was founded on 29-09-2020.
Is MAYAKU PHARMACEUTICAL DEVELOPMENT still active?
Yes, MAYAKU PHARMACEUTICAL DEVELOPMENT is an active enterprise in the KBO register.
How many employees does MAYAKU PHARMACEUTICAL DEVELOPMENT have?
MAYAKU PHARMACEUTICAL DEVELOPMENT had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of MAYAKU PHARMACEUTICAL DEVELOPMENT?
The turnover in financial year 2025 is about €260,000. This figure is estimated from the gross margin of €104,752 and 2,458 comparable companies of the same size. It probably lies between €170,000 and €410,000. It is a rough estimate.
Is MAYAKU PHARMACEUTICAL DEVELOPMENT profitable?
In financial year 2025, MAYAKU PHARMACEUTICAL DEVELOPMENT made a profit of €1,553.
Where can I find the annual accounts of MAYAKU PHARMACEUTICAL DEVELOPMENT?
MAYAKU PHARMACEUTICAL DEVELOPMENT filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MAYAKU PHARMACEUTICAL DEVELOPMENT due?
MAYAKU PHARMACEUTICAL DEVELOPMENT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.